OpenLB
Open Library of Bioscience
Advanced Search
Hepatology research : the official journal of the Japan Society of Hepatology
Mar, 2020;50 (3): 374-381.

Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.

Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro
Author Information
  1. Teiji Kuzuya: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ORCID
  2. Masatoshi Ishigami: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ORCID
  3. Takanori Ito: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ORCID
  4. Yoji Ishizu: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ORCID
  5. Takashi Honda: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  6. Tetsuya Ishikawa: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  7. Mitsuhiro Fujishiro: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
PMID: 31721363 DOI: 10.1111/hepr.13452

Abstract

AIM: We aimed to investigate the radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma in real-world practice.
METHODS: This retrospective study enrolled 40 patients who received lenvatinib. Radiological antitumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors.
RESULTS: The objective response rate at 2 weeks and best overall response on confirmation of complete response, partial response (PR), and stable disease required (confirmed response) were 57.5% and 32.5%, respectively. Based on confirmed response, the overall survival rate was significantly longer in patients with an objective response rate than in those with stable disease or progressive disease after 12 months (73.2% and 54.2%, P = 0.0358). All 13 patients with an objective response rate on confirmed response were evaluated as PR at 2 weeks. The alpha-fetoprotein ratio at 2 weeks was a significant factor associated with PR of response rate at 2 weeks. The median relative dose intensity from 2 to 6 weeks was significantly lower than that from 0 to 2 weeks (69.6% vs. 100%, P < 0.0001). Stratified by the antitumor response at 6 weeks considering the image evaluation at 2 weeks, the median relative dose intensity from 2 to 6 weeks was significantly lower in patients with progressive disease than in those with PR or stable disease (45.2% vs. 72.6%, P = 0.0482).
CONCLUSIONS: The radiological antitumor response at 2 weeks was favorable. Information on a favorable visible therapeutic response very early after lenvatinib initiation can help patients maintain their motivation for treatment, and allow physicians to continue treatment effectively and safely.

Keywords

alpha-fetoprotein hepatocellular carcinoma lenvatinib modified Response Evaluation Criteria in Solid Tumors relative dose intensity

References

  1. Yamamoto Y, Matsui J, Matsushima T et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014; 6: 18.
  2. Ikeda M, Okusaka T, Mitsunaga S et al. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2016; 22: 1385-1394.
  3. Ikeda K, Kudo M, Kawazoe S et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52: 512-519.
  4. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173.
  5. Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol 2018; 69: 237-247.
  6. Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res 2018; 48: 597-607.
  7. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15: 599-616.
  8. Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opin Drug Saf 2018; 17: 1095-1105.
  9. Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers (Basel) 2018; 10: E412.
  10. Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol 2019; 70: 1262-1277.
  11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
  12. Kuzuya T, Ishigami M, Ishizu Y et al. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2015; 10: e0138776.
  13. Kuzuya T, Ishigami M, Ishizu Y et al. Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology 2016; 91: 261-266.
  14. Hiraoka A, Kumada T, Kariyama K et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res 2019; 49: 111-117.
  15. Hiraoka A, Kumada T, Kariyama K et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 2019; 8: 137-146.
  16. Hiraoka A, Kumada T, Atsukawa M et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019; 8: 3719-3728.
  17. Hiraoka A, Kumada T. Atsukawa M, et al: OncologyImportant Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma, 2019 [Epub ahead of print].
  18. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
  19. Raoul JL, Park JW, Kang YK et al. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer 2014; 3: 439-450.
  20. Kuzuya T, Asahina Y, Tsuchiya K et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 251-258.
  21. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-458.
  22. Obi S, Sato T, Sato S et al. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int 2019; 13: 199-204.
  23. Koizumi Y, Hirooka M, Hiraoka A et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J 2019[Epub ahead of print]; 66: 787-792.
  24. Kodama K, Kawaoka T, Namba M et al. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. Oncology 2019; 97: 75-81.
  25. Kaneko S, Tsuchiya K. Kurosaki M, et al: Hepatol ResThe three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib, 2019 [Epub ahead of print].
  26. Ueshima K, Nishida N, Hagiwara S et al. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers (Basel) 2019; 11: E952.
  27. Lencioni R, Montal R, Torres F et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66: 1166-1172.
  28. Kudo M. Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer 2018; 7: 215-224.
  29. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  30. Kuroda H, Abe T, Fujiwara Y et al. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25: 2365-2372.
  31. Takeda H, Nishijima N, Nasu A et al. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. Hepatol Res 2019; 49: 594-599.
  32. Robinson B, Schlumberger M, Wirth LJ et al. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab 2016; 101: 4103-4109.
Journal Article

Word Cloud

Created with Highcharts 10.0.0response2 weekspatientsantitumorlenvatinibratediseasePRradiologicalhepatocellularcarcinomaobjectivestableconfirmedsignificantly2%relativedoseintensity6 weeksstartingadvancedevaluatedmodifiedResponseEvaluationCriteriaSolidTumorsoverall5%progressiveP = 0alpha-fetoproteinmedian2lower6%vsfavorabletreatmentAIM:aimedinvestigatereal-worldpracticeMETHODS:retrospectivestudyenrolled40receivedRadiologicalaccordingRESULTS:bestconfirmationcompletepartialrequired5732respectivelyBasedsurvivallonger12 months7354035813ratiosignificantfactorassociated069100%P < 00001Stratifiedconsideringimageevaluation45720482CONCLUSIONS:InformationvisibletherapeuticearlyinitiationcanhelpmaintainmotivationallowphysicianscontinueeffectivelysafelyFavorable

Similar Articles

Cited By